Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Tjon Pian Gi, RE; Ilmarinen, T; van den Heuvel, ER; Aaltonen, LM; Andersen, J; Brunings, JW; Chirila, M; Dietz, A; Ferran Vilà, F; Friedrich, G; de Gier, HH; Golusinski, W; Graupp, M; Hantzakos, A; Horcasitas, R; Jackowska, J; Koelmel, JC; Lawson, G; Lindner, F; Remacle, M; Sittel, C; Weichbold, V; Wierzbicka, M; Dikkers, FG.
Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.
Eur Arch Otorhinolaryngol. 2013; 270(5):1679-1687
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Friedrich Gerhard
Graupp Matthias
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Intralesional use of cidofovir (Vistide(®)) has been one of the mainstays of adjuvant therapy in patients with recurrent respiratory papillomatosis (RRP) since 1998. In 2011, a communication provided by the producer of cidofovir addressed very serious side effects concerning its off-label use. As this was a general warning, it was inconclusive whether this would account for its use in RRP. The aim of this study is to determine whether nephrotoxic, neutropenic, or oncogenic side effects have occurred after intralesional use of cidofovir in patients with RRP. Update of recent developments in RRP, a multicentre questionnaire and a multicentre retrospective chart review. Sixteen hospitals from eleven countries worldwide submitted records of 635 RRP patients, of whom 275 were treated with cidofovir. RRP patients received a median of three intralesional injections (interquartile range 2-6). There were no statistical differences in occurrence of neutropenia or renal dysfunction before and after cidofovir. There was no statistical difference in occurrence of upper airway and tracheal malignancies between the cidofovir and the non-cidofovir group. In this retrospective patient chart review, no clinical evidence was found for more long-term nephrotoxicity, neutropenia or laryngeal malignancies after the administration of intralesional cidofovir in RRP patients.
Find related publications in this database (using NLM MeSH Indexing)
Antiviral Agents - adverse effects
Combined Modality Therapy -
Cytosine - adverse effects
Female -
Head and Neck Neoplasms - chemically induced
Humans -
Injections, Intralesional -
Male -
Neutropenia - chemically induced
Off-Label Use -
Organophosphonates - adverse effects
Papillomavirus Infections - drug therapy
Renal Insufficiency - chemically induced
Respiratory Tract Infections - drug therapy
Retrospective Studies -
Treatment Outcome -

Find related publications in this database (Keywords)
Recurrent respiratory papillomatosis
RRP
Laryngeal papilloma
Cidofovir
Side effects
Nephrotoxicity
Neutropenia
Malignancy
© Med Uni Graz Impressum